Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 122

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 122
---
 samples can delay development timelines and increase costs of development. Generally, the agreements under which we gain access to human samples are non -exclusive. Other companies may compete with us for access. Additionally, the process of negotiating access to samples can be lengthy and it may involve numerous parties and approval levels to resolve complex issues such as usage rights, institutional review board approval, privacy rights, publication rights, intellectual property ownership, and research parameters. If we are not able to negotiate access to clinical samples with research institutions, hospitals, clinical partners, pharmaceutical companies, or companies developing therapeutics on a timely basis, or at all, or if other laboratories or our competitors secure access to these samples before us, our ability to research, develop and commercialize future products will be limited or delayed. We aimed for high standards in clinical research, which involves following current ethical recommendations and conducting clinical studies under Good Clinical Practices (“GCP”). Any failure in these standards may lead to delays in product developments, lack of confidence in the results of the test, or inability to get approval by local regulatory agencies. Finally, we may not be able to conduct or complete clinical studies on a timely basis if we are not able to enroll sufficient numbers of patients in such studies, and our failure to do so could have an adverse effect on our research and development and product commercialization efforts, which would have an adverse impact on our business, financial condition, results of operations and growth prospects. If any of our laboratories or other facilities become inoperable or if we otherwise experience a significant disruption in our operations for any reason, we will be unable to perform our tests and our business would be harmed. We currently perform our main research and development operations in our Argentine Wet -Labin Rosario, Argentina. Our current headquarters are located in Rosario, Argentina. If our present, or any future facilities, were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, storms, tornadoes, earthquakes, other inclement weather events or natural disasters, employee malfeasance, terrorist acts, power outages, or otherwise, it may render it difficult or impossible for us to perform our tests for some period of time and our business could be severely disrupted. Our facilities and the equipment we use to perform our tests would be costly to replace and could require substantial lead time to repair or replace. The inability to perform our tests or the backlog of tests that could develop if any of our facilities become inoperable for even a short period of time may result in the loss of customers